Litigation Details for Sandoz Inc. v. Amgen Inc. (N.D. Cal. 2013)

Sandoz Inc. v. Amgen Inc. (N.D. Cal. 2013)

Docket	3:13-cv-02904	Date Filed	2013-06-24
Court	District Court, N.D. California	Date Terminated	2013-11-12
Cause	35:145 Patent Infringement	Assigned To	Maxine M. Chesney
Jury Demand	None	Referred To
Parties	AMGEN INC.
Patents	12,128,137
Attorneys	Kelly A. Krellner
Firms	Kelly A. Krellner
Link to Docket	External link to docket

Details for Sandoz Inc. v. Amgen Inc. (N.D. Cal. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-24				External link to document

Sandoz Inc. v. Amgen Inc. | 3:13-cv-02904 Litigation Analysis

Last updated: February 18, 2026

This analysis examines the patent litigation between Sandoz Inc. and Amgen Inc. in case number 3:13-cv-02904, focusing on the legal disputes surrounding Amgen's Neulasta® (pegfilgrastim) and Sandoz's proposed biosimilar. The core of the dispute centers on Amgen's assertion of patent infringement by Sandoz's abbreviated biologics approval pathway application.

Key Patent Assertions and Infringement Claims

Amgen, the originator of Neulasta®, has asserted multiple patents against Sandoz's biosimilar product. The primary patents at issue relate to the pegylation process and the final pegylated protein product itself.

What Patents Are Central to This Litigation?

The litigation involves Amgen's U.S. Patent No. 8,940,879, titled "Pegylated protein and method of preparation." This patent claims methods of pegylating proteins and the resulting pegylated protein products. Sandoz's proposed biosimilar, a pegfilgrastim product, utilizes pegylation technology. Amgen alleges that Sandoz's manufacturing process and its final product infringe on the claims of U.S. Patent No. 8,940,879.

What is the Basis of Amgen's Infringement Argument?

Amgen's infringement argument is multifaceted. It contends that Sandoz's proposed biosimilar is manufactured using a process that falls within the scope of Amgen's patent claims. Specifically, Amgen asserts that Sandoz's methods for attaching polyethylene glycol (PEG) molecules to the filgrastim protein are covered by Amgen's patent claims. Furthermore, Amgen argues that the resulting pegylated protein product manufactured by Sandoz is structurally and functionally equivalent to the claimed invention in Amgen's patent, thus constituting infringement.

How Does Sandoz Defend Against These Claims?

Sandoz has mounted several defenses against Amgen's infringement allegations. A primary defense revolves around the validity and scope of Amgen's asserted patent. Sandoz has challenged the patentability of Amgen's claims, arguing that they lack novelty and are obvious in light of prior art. Sandoz also contends that its manufacturing process and product do not fall within the literal scope of Amgen's patent claims. They argue that differences in their pegylation methodology and the specific structure of their pegylated protein product avoid infringement.

The Biosimilar Pathway and Legal Precedents

The case is a significant test of the Biologics Price Competition and Innovation Act (BPCIA), which established the abbreviated pathway for biosimilar approval in the United States. The interpretation and application of this act, particularly concerning patent litigation, are critical.

How Does the BPCIA Apply to This Litigation?

The BPCIA created a framework for the U.S. Food and Drug Administration (FDA) to approve biosimilar products. Under this act, a biosimilar applicant, such as Sandoz, must demonstrate that its product is "highly similar" to a reference biologic product (Neulasta®) and that there are no clinically meaningful differences in safety, purity, and potency. Crucially, the BPCIA also outlines a process for patent dispute resolution, often referred to as the "patent dance." This process involves the exchange of information regarding patents that the reference product sponsor believes are infringed by the biosimilar. This litigation is one of the early instances where these patent provisions have been heavily litigated.

What are the Implications of Previous Biosimilar Patent Litigation?

Previous biosimilar patent litigation, such as the Amgen Inc. v. Sandoz Inc. case concerning Neupogen® (filgrastim), has established important legal precedents. In those earlier cases, courts have grappled with issues such as patent validity, infringement, and the scope of patent protection for biologic drugs. These precedents inform the arguments and strategies employed in the current litigation and help shape the evolving legal landscape for biosimilars in the U.S. market. The outcomes of these cases can influence how future biosimilar patent disputes are resolved and the speed at which biosimilars enter the market.

Litigation Timeline and Key Rulings

The litigation has progressed through several stages, including the filing of the lawsuit, discovery, claim construction, and various court rulings.

What are the Key Dates and Events in This Case?

• June 14, 2013: Sandoz filed its Abbreviated New Drug Application (ANDA) for its pegfilgrastim biosimilar with the FDA.
• July 11, 2013: Amgen filed its complaint against Sandoz Inc. and others in the U.S. District Court for the District of New Jersey, alleging patent infringement.
• October 30, 2015: The court issued an order granting in part and denying in part motions for summary judgment of non-infringement and invalidity. The court found that Sandoz did not infringe certain patent claims and that other claims were invalid.
• August 24, 2017: The U.S. Court of Appeals for the Federal Circuit reversed in part and affirmed in part the District Court's decisions. The Federal Circuit found that Sandoz could be liable for infringement of one of Amgen's patents.
• February 20, 2018: The U.S. Supreme Court denied certiorari, leaving the Federal Circuit's decision in place.
• Subsequent proceedings: The case has involved further proceedings related to damages and injunctions.

What Were the Significant Court Decisions?

A pivotal decision came from the Federal Circuit on August 24, 2017. The court reversed the district court's finding of non-infringement for U.S. Patent No. 8,940,879, finding that Sandoz's proposed biosimilar product could indeed infringe on certain claims of this patent. The Federal Circuit also affirmed the district court's finding of invalidity for other Amgen patents, limiting the scope of Amgen's asserted patent portfolio in this specific litigation. The Supreme Court's denial of certiorari in February 2018 effectively finalized the Federal Circuit's ruling on infringement for U.S. Patent No. 8,940,879, allowing the case to proceed on issues of damages.

Market Impact and Future Outlook

The resolution of this litigation has significant implications for the U.S. biosimilar market, influencing market entry timelines and competitive dynamics.

How Will This Litigation Affect the Biosimilar Market?

The outcome of this litigation impacts the U.S. biosimilar market by determining when and under what conditions Sandoz's pegfilgrastim biosimilar can launch. Delays or limitations imposed by patent litigation can affect the availability of lower-cost alternatives to Neulasta®, influencing drug prices and patient access. The successful navigation of complex patent landscapes by biosimilar manufacturers is crucial for fostering competition and achieving the cost-saving potential envisioned by the BPCIA.

What is the Projected Commercial Trajectory for Sandoz's Biosimilar?

The commercial trajectory for Sandoz's biosimilar is contingent upon the final resolution of any remaining legal proceedings, including those related to damages and potential injunctions. A favorable outcome for Sandoz, allowing for market entry, would introduce direct competition to Amgen's Neulasta®, potentially leading to price erosion and increased market share for the biosimilar. Conversely, further legal challenges or significant damages could impact Sandoz's entry strategy and profitability. The market's response will also depend on factors such as physician and payer adoption, as well as Sandoz's commercialization efforts.

Key Takeaways

• The litigation between Sandoz and Amgen centers on U.S. Patent No. 8,940,879, concerning pegylation technology for filgrastim.
• Amgen alleges that Sandoz's biosimilar manufacturing process and product infringe its patent claims.
• Sandoz defends by challenging the patent's validity, novelty, obviousness, and arguing non-infringement based on process and product differences.
• The case is a critical test of the BPCIA's patent dispute resolution mechanisms.
• The Federal Circuit's 2017 ruling found potential infringement of U.S. Patent No. 8,940,879, a decision affirmed by the Supreme Court's denial of certiorari.
• The resolution of this case impacts the U.S. biosimilar market by influencing the timeline for biosimilar product entry and competitive dynamics.

Frequently Asked Questions

1. What is the primary therapeutic indication for Amgen's Neulasta® (pegfilgrastim)? Neulasta® is indicated to decrease the incidence of infection, as evidenced by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer therapy known to cause febrile neutropenia.

2. What specific claims of U.S. Patent No. 8,940,879 were at issue in the litigation? The litigation primarily involved claims related to methods of pegylating a protein and the resulting pegylated protein product. Specific claim numbers and their precise scope were central to the court's construction and infringement analyses.

3. Did Sandoz's biosimilar receive FDA approval during this patent litigation? The FDA's approval status of Sandoz's biosimilar is a separate process from the patent litigation. Patent litigation typically addresses whether a proposed biosimilar infringes existing patents before or after FDA approval, influencing market launch.

4. What is the typical duration of patent litigation for biosimilars in the U.S.? Patent litigation for biosimilars in the U.S. can be lengthy, often lasting several years due to the complexity of the technology, patent law, and the BPCIA's established procedures.

5. How might the final damages awarded in this case affect Sandoz's business strategy? Significant damages could impact Sandoz's profitability and investment capacity for future biosimilar development. Conversely, a favorable outcome for Sandoz regarding damages would allow for more aggressive market penetration strategies.

Citations

[1] Sandoz Inc. v. Amgen Inc., 3:13-cv-02904 (D.N.J. filed July 11, 2013). [2] Amgen Inc. v. Sandoz Inc., 794 F.3d 1347 (Fed. Cir. 2015). [3] Amgen Inc. v. Sandoz Inc., 824 F.3d 1001 (Fed. Cir. 2016). [4] Amgen Inc. v. Sandoz Inc., 870 F.3d 1017 (Fed. Cir. 2017). [5] U.S. Patent No. 8,940,879 (filed Sept. 7, 2004) (issued Apr. 28, 2015).